BRAIN CANCER

Latest News

FDA Receives Rolling NDA of Tovorafenib for Pediatric Low-Grade Glioma
FDA Receives Rolling NDA of Tovorafenib for Pediatric Low-Grade Glioma

September 14th 2023

Data from the phase 2 FIREFLY-1 trial support the new drug application for tovorafenib in relapsed or progressive pediatric low-grade glioma. The regulatory agency anticipates filing the application by mid-November 2023

Could VAL-083 Address Modest Treatment Efficacy in Glioblastoma?
Could VAL-083 Address Modest Treatment Efficacy in Glioblastoma?

August 24th 2023

Favorable Immune Profile Linked to VT1021 Treatment Response in rGBM
Favorable Immune Profile Linked to VT1021 Treatment Response in rGBM

August 24th 2023

Crafting Targeted Treatments in Pediatric Low-Grade Glioma Improves Results
Crafting Targeted Treatments in Pediatric Low-Grade Glioma Improves Results

August 4th 2023

FDA Grants Orphan Drug Designation to ABM-1310 for Glioblastoma
FDA Grants Orphan Drug Designation to ABM-1310 for Glioblastoma

August 3rd 2023